Skip to content
    COR
    Earnings call· Mar 2026(Q2 FY26)

    Cencora Q2 FY26 earnings call COR

    May 6, 2026 Source

    Executive summary

    Cencora Q2 FY26 — EPS +7.5%, EPS/OI guidance raised, buybacks resume amid transitory revenue headwinds

    Cencora framed a quarter where resilient operating-income growth was masked by transitory, largely low-margin revenue noise — WAC price cuts, slower GLP-1s, and faster mail-order biosimilar conversion that dents revenue while enriching margin mix. Management held segment operating-income guidance, leaned on specialty/MSO integration and an international specialty-logistics recovery, and pivoted back toward capital return.

    Highlights

    5

    • Adjusted diluted EPS of $4.75, up 7.5% YoY, on track to raised FY26 guidance of $17.65-$17.90

    • Consolidated operating income of $1.3B, up 6%, with growth in both US and International Healthcare Solutions segments; consolidated gross profit $3.4B, up 16%

    • International Healthcare Solutions operating income up ~14% as-reported (13% constant currency), aided by a second consecutive quarter of operating-income growth at global specialty logistics (World Courier)

    • Raised FY26 consolidated operating-income growth guidance to 12-14% (from 11.5-13.5%) and adjusted EPS to $17.65-$17.90 (from $17.45-$17.75)

    • Resumed opportunistic share repurchases, targeting $1B of buybacks by calendar year-end, alongside $500M of term-loan paydown YTD

    Concerns

    5

    • Consolidated FY26 revenue growth guidance cut to 4-6% from 7-9% (US Healthcare Solutions likewise cut to 4-6%)

    • $2B revenue headwind in the quarter from manufacturer/IRA WAC list-price reductions, a ~3% drag on US revenue growth

    • GLP-1 revenue growing slower than expected — a 5% delta in growth represents ~$2B of annual revenue

    • Faster-than-expected brand-to-biosimilar conversions at the large mail-order pharmacy customer pressuring revenue

    • Transitory ~$10M weather and ~$10M COVID-19 vaccine operating-income headwinds, plus the not-yet-lapped July 2025 oncology-customer loss

    Guidance & targets

    16
    CategoryTargetConfidence
    Full-year FY26 adjusted diluted EPS
    $17.65 to $17.90
    high materiality
    High
    Full-year FY26 consolidated revenue growth
    4% to 6%
    high materiality
    High
    Full-year FY26 US Healthcare Solutions revenue growth
    4% to 6%
    high materiality
    High
    Full-year FY26 International Healthcare Solutions revenue growth (as-reported)
    8% to 10%
    medium materiality
    High
    Full-year FY26 International Healthcare Solutions revenue growth (constant currency)
    6% to 8%
    low materiality
    High
    Full-year FY26 consolidated operating income growth
    12% to 14%
    high materiality
    High
    Full-year FY26 US Healthcare Solutions operating income growth
    14% to 16%
    high materiality
    High
    Full-year FY26 International Healthcare Solutions operating income growth
    5% to 8%
    medium materiality
    High
    Full-year FY26 Other segment operating income growth
    High-single-digit percent
    medium materiality
    Medium
    Full-year FY26 net interest expense
    Approximately $485M
    medium materiality
    High
    Full-year FY26 adjusted free cash flow
    Approximately $3B
    medium materiality
    High
    Full-year FY26 diluted shares outstanding
    Under 195.5 million shares
    medium materiality
    Medium
    Share repurchases
    $1 billion of shares repurchased
    high materiality
    High
    Term-loan paydown
    $1.3 billion of term loans
    medium materiality
    High
    Q3 FY26 adjusted diluted EPS growth
    High single digits
    medium materiality
    Medium
    Long-term organic operating income growth
    7% to 10%
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    U.S. Healthcare Solutions
    Volume growth in specialty (health systems and physician practices) and GLP-1s offset by manufacturer list-price reductions, the FY25 oncology and grocery customer losses, and faster-than-expected mail-order brand-to-biosimilar conversions (low-margin, revenue-concentrated). Oncology-customer-loss headwind exceeded the OneOncology contribution this quarter; strongest growth expected in Q4.
    GLP-1 sales growth: +$1.9B YoYWAC/IRA list-price reduction revenue headwind: $2B (~3% US revenue drag)Weather operating-income headwind: ~$10MCOVID-19 vaccine operating-income headwind: ~$10M (vs $15M contribution in Q2 FY25)Core segment OI growth ex-OneOncology and ex-oncology-customer-loss: ~7%
    		$68.8B+3%—Operating income $998M, +6%
    International Healthcare Solutions
    Growth led by European distribution plus a timing shift of manufacturer price adjustments in a developing-market country (flagged last quarter) and continued World Courier rebound with volume and operating-income growth.
    European distribution (Alliance Healthcare): primary revenue driverGlobal specialty logistics (World Courier): second consecutive quarter of operating-income growth
    		$7.6B+13% as-reported / +7% constant currency—Operating income $176M, +~14% as-reported / +13% constant currency
    Other
    Revenue growth from Pro Pharma and MWI Animal Health, partly offset by the expected decline in legacy US hub consulting services; operating income down slightly on the US hub consulting manufacturer-program loss, partly offset by MWI growth.
    MWI Animal Health: operating-income growth (now classified asset held for sale, depreciation suspended)US hub consulting services: revenue decline (divested April 30) and FY25 loss of a manufacturer program
    		$2.1B+5%—Operating income $92M, -1%

    Operational metrics

    9
    Gross profit margin
    4.31%+45 bps YoY
    Q2 FY26

    Consolidated gross profit was $3.4B, up 16%, primarily from US Healthcare Solutions; MSO income-statement shape differs from core distribution. Non-GAAP.

    Operating expense growth
    +22.5%vs prior-year quarter
    Q2 FY26

    Consolidated operating expenses were $2.1B; core expense growth expected to moderate in the back half, particularly Q4 on easier US comps. Management stressed viewing operating leverage ex-MSO.

    Effective income tax rate
    18.9%vs 20.8% in prior-year quarter
    Q2 FY26

    Non-GAAP effective tax rate.

    Net interest expense
    $140M+$36M YoY
    Q2 FY26

    Q3 net interest expense expected roughly flat at ~$140M, modestly stepping down in Q4.

    Diluted share count
    195.4 million+0.1% YoY
    Q2 FY26

    Compared to prior-year second quarter; buybacks resuming with FY diluted shares guided under 195.5M.

    Manufacturer/IRA WAC list-price reduction revenue impact
    $2B revenue headwind~3% drag on US revenue growth
    Q2 FY26

    Fully contemplated in guidance; a driver of below-expectations US revenue but not operating income. IRA-related manufacturer WAC reductions.

    Weather operating-income headwind
    $10M
    Q2 FY26

    Transitory US segment headwind given Cencora's leading presence in the physician channel.

    COVID-19 vaccine operating-income headwind
    $10Mvs $15M contribution in Q2 FY25
    Q2 FY26

    Lower COVID vaccine demand turned a prior-year contribution into a headwind for the US segment.

    Term-loan paydown
    $500Mtoward $1.3B planned for the fiscal year
    FY26 year-to-date

    Debt raised in February for OneOncology being paid down; supports the ~$3B FCF target.

    Industry KPIs

    3
    MetricValueDetails
    Pharmacy scripts specialtyGLP-1 sales grew +$1.9B YoYUSD
    Segment revenue operating incomeUS Healthcare Solutions revenue $68.8B (+3%), operating income $998M (+6%); International revenue $7.6B (+13% as-reported/+7% cc), operating income $176M (+~14%/+13% cc); Other revenue $2.1B (+5%), operating income $92M (-1%)USD
    Adjusted EPS EBITDA leverage guidanceAdjusted diluted EPS $4.75 (+7.5%); FY26 adjusted EPS guidance raised to $17.65-$17.90USD / %

    Product announcements

    2
    ProductTypeDetails
    AI-supported customer support toolslaunch
    Accelerate Pharmacy Solutions portfolioexpansion

    Deals & partnerships

    4
    OneOncologyacquisition

    MSO platform now fully owned and being integrated with RCA via joint teams (research/clinical trials, back-office, physician recruitment/retention). Financed by debt raised in February (added ~$36M net interest expense).

    Covetrusmerger

    Agreement to merge MWI Animal Health with Covetrus as part of portfolio-focus/optimization toward the pharmaceutical-centric strategy.

    U.S. hub consulting services buyer (unnamed)divestiture

    Sale of legacy US hub consulting services, positioning the business with a strategically aligned partner and supporting portfolio focus.

    iSouth (South)acquisition

    MSO bolt-on acquisition; RCA has lapped its one-year annualization while OneOncology continues to ramp. Management sees good bolt-on opportunities across MSO platforms.

    Risks & headwinds

    8
    Slower GLP-1 revenue growth than expectedFY26 and beyond; additional GLP-1 price reductions flagged for 1/1/2027

    A 5% growth delta represents ~$2B in annual revenue; GLP-1s grew +$1.9B YoY in Q2 but at a slower pace than expected

    Mitigation: Low-margin category; company guides on operating income, not revenue; confident in recouping value through service scope/scale

    Manufacturer/IRA WAC list-price reductionsOngoing through FY26 policy cycle

    $2B revenue headwind in Q2 (~3% US revenue drag)

    Mitigation: Fully contemplated in guidance; low margin so limited operating-income impact; Cencora has been able to recoup the value of WAC changes

    Faster-than-expected brand-to-biosimilar conversion at large mail-order customerFY26

    Meaningful contributor to reduced FY revenue-growth guidance (4-6% from 7-9%); not a meaningful operating-income driver (low-margin brand sales)

    Mitigation: Consistent with the existing model (products typically leave the wholesaler when in-sourced); higher margins for Cencora overall; Part B biosimilar conversion is incrementally beneficial

    Not-yet-lapped loss of oncology customer (acquisition-driven)Laps on July 1, 2026

    Operating-income headwind larger than the Q2 OneOncology contribution; began hitting numbers July 2025

    Mitigation: OneOncology accretion ramping; back-half/Q4 acceleration expected once lapped

    Transitory weather-related physician volume softnessLate January/early February; rebounded March-April

    ~$10M US segment operating-income headwind in Q2

    Mitigation: Patient appointments and specialty volumes rebounded in March with good April trends

    Lower COVID-19 vaccine demandQ2 FY26

    ~$10M operating-income headwind vs $15M contribution in Q2 FY25

    Mitigation: Transitory; not expected to recur at prior-year contribution levels

    Loss of a grocery customer (previously disclosed)FY25 loss carrying into FY26

    Impacted revenue growth in the quarter; not called out as an operating-income impact

    Mitigation: Contemplated in guidance; smaller customer moves are absorbed within guidance

    Biosimilar erosion of Part D mail revenueOngoing

    Revenue hit as products move brand-to-biosimilar and away from the wholesaler; not a meaningful profit hit

    Mitigation: Already part of the existing model; Part B biosimilar growth is incrementally beneficial to Cencora and practices

    Q&A highlights

    11

    How do WAC/IRA reductions, lost business and the lower-margin mail shift affect operating profit, and do they change long-term revenue or operating-profit growth rates?

    Cleary walked through Q2 revenue drivers (specialty volume, GLP-1 +$1.9B) and headwinds ($2B WAC/IRA = 3% US revenue drag, oncology/grocery customer losses, faster mail brand conversions), then operating-income drivers, and reaffirmed the long-term algorithm of 7-10% organic OI growth + 3-4% capital deployment = 10-14% EPS growth. Mauch added that revenue-pressuring items are low-margin and Cencora recoups WAC-decrease value, which is why they guide on operating income.

    “we continue to have confidence in our long-term guidance, which is, of course, 7% to 10% organic operating income growth, another 3% to 4% from capital deployment and 10% to 14% EPS growth.”

    asked by Lisa Gill · answered by James Cleary

    2 min read6 chapters

    Detailed Narrative

    01

    Quarter framed as resilient earnings amid transitory revenue noise

    Cencora delivered adjusted diluted EPS of $4.75 (+7.5%) and consolidated operating income of $1.3B (+6%), with growth in both reportable segments. Management repeatedly characterized the below-expectations revenue print as driven by transitory📎 or low-margin items — WAC/IRA price reductions ($2B revenue headwind, ~3% US drag), slower GLP-1 growth, and faster mail-order biosimilar conversion — none of which meaningfully hit operating income. Consolidated revenue was $78.4B (+4%) and gross profit $3.4B (+16%), lifting gross margin 45 bps to 4.31%, largely from the OneOncology acquisition.

    02

    Revenue guidance cut, operating-income and EPS guidance raised

    The company cut FY26 consolidated and US revenue growth guidance to 4-6% (from 7-9%) on slower GLP-1s (a 5% growth delta equals ~$2B annual revenue) and faster branded-to-biosimilar conversion at the large mail-order customer. Simultaneously it raised FY26 adjusted EPS to $17.65-$17.90 and consolidated operating-income growth to 12-14%. Segment operating-income guidance held (US 14-16%, International 5-8%) while Other rose to high-single-digit growth on MWI held-for-sale depreciation suspension. Back-half growth is expected to accelerate, strongest in Q4.

    03

    Specialty, MSO integration and portfolio focus

    Cencora completed full ownership of OneOncology in February 2026 and is integrating it with RCA, forming joint teams across research/clinical trials, back-office and physician recruitment. Management stressed Part B biosimilar conversion is incrementally beneficial to practices and Cencora, whereas Part D mail conversion is mainly a low-margin revenue hit. Portfolio focus steps included the MWI-Covetrus merger agreement, the April 30 divestiture of US hub consulting services, and the announced iSouth MSO bolt-on (not in FY26 guidance).

    04

    International rebound led by World Courier

    International Healthcare Solutions revenue was $7.6B, up 13% as-reported (7% cc), with operating income of $176M up ~14% as-reported (13% cc). Growth was driven by European distribution (Alliance Healthcare), a shift in timing of📎 manufacturer price adjustments in a developing-market country, and a second consecutive quarter of operating-income growth at the global specialty logistics business (World Courier). Management cited commercial rightsizing, pricing discipline and efficiency, plus volume growth, and expects continued growth aided by easier back-half comps.

    05

    Capital deployment pivots back toward buybacks

    With acquisition-driven pause ending, Cencora resumed opportunistic share repurchases, targeting $1B of buybacks by calendar year-end and full-year diluted shares under 195.5M. It has paid down $500M of term loans YTD toward a $1.3B FY plan and reaffirmed ~$3B adjusted free cash flow ($1.1B generated in the March quarter; $2.2B cash on hand). Balanced capital deployment continues to span CapEx (with strong returns), strategic M&A, buybacks and a growing dividend. Net interest expense guidance improved to ~$485M.

    06

    CFO transition

    This was CFO Jim Cleary's final earnings call ahead of his retirement as CFO in June 2026 and departure from the company in December 2026. CEO Bob Mauch acknowledged Cleary's years of service and partnership.

    AI-generated summary of the company’s earnings call. Not investment advice.